Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $21.84B | $20.18B | $19.37B | $18.87B | $19.13B | $16.07B | $17.29B | $15.98B |
| Cost of Revenue | $11.91B | $11.05B | $11.20B | $10.39B | $10.50B | $9.28B | $9.00B | $8.71B |
| Gross Profit | $9.92B | $9.13B | $8.17B | $8.48B | $8.63B | $6.80B | $8.29B | $7.27B |
| Gross Margin | 45.44% | 45.22% | 42.17% | 44.92% | 45.12% | 42.29% | 47.94% | 45.48% |
| Operating Expenses | $7.35B | $6.73B | $6.06B | $6.20B | $6.38B | $5.89B | $6.53B | $5.76B |
| Operating Income | $2.58B | $2.40B | $2.11B | $2.28B | $2.25B | $912.00M | $1.76B | $1.51B |
| Operating Margin | 11.80% | 11.88% | 10.90% | 12.09% | 11.76% | 5.67% | 10.18% | 9.44% |
| Net Income | $1.68B | $1.71B | $1.48B | $1.78B | $2.09B | $874.00M | $1.23B | $311.00M |
| Net Margin | 7.68% | 8.45% | 7.66% | 9.43% | 10.94% | 5.44% | 7.13% | 1.95% |
| EPS (Basic) | $5.84 | $5.88 | $4.97 | $5.93 | $6.92 | $2.75 | $3.96 | $0.62 |
| EBITDA | $4.96B | $4.82B | $4.40B | $4.41B | $4.39B | $3.06B | $4.07B | $3.86B |
| Stock Option Compensation Expense | $258.00M | $247.00M | $259.00M | $233.00M | $229.00M | $236.00M | $261.00M | $322.00M |
| Price To Earnings Ratio | 31.97 | 40.97 | 49.87 | 35.70 | 33.14 | 72.41 | 53.99 | 214.12 |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | $53.65B | $69.86B | $74.01B | $63.51B | $69.33B | $63.28B | $66.57B | $66.59B |